secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001493152-24-040523
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced
--------------------------------------------------------------------------------

- ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.
- $4.45M public offering closed Sep 2024; total $6M+ raised in 2024 to fund Phase II trial.
- Phase II trial planned later 2024, first in Australia then U.S.; evaluates efficacy on symptom reduction and functional recovery.
- Appointed Dr. James Kelly as CMO and Dr. William Peacock as CCO in 2024 for clinical oversight.
- Partnership with Avance Clinical in May 2024; Australian Regulatory Submission Brochure targeted Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224040523/0001493152-24-040523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224040523/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer